



Advances in Cardiovascular Pharmacology: The Era of Targeted Therapies in Cardiology 3.0

Guest Editors:

Prof. Dr. Pietro Scicchitano

Cardiology Department, Perinei
Hospital, Bari, Italy

Dr. Francesco Massari

Cardiology Department, Perinei
Hospital, Bari, Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Despite primary and secondary prevention protocols, the mortality and morbidity rates still remain higher (about 4–17%).

Cardiovascular pharmacology is now facing a new approach to cardiac diseases: the molecular “influence” of gene transcription and transduction in order to target the inner mechanism which could be responsible for the onset and progression of CVDs.

Recent innovations in the field of non-invasive treatment of CVDs are focusing on three main issues: 1. specifically identifying and treating the core cause of the illness; 2. avoiding adverse events related to pharmacological treatments; 3. improving adherence to and persistence on therapies.

The aim of this Special Issue is to provide a dedicated overview of new pharmacological approaches to CVDs.

Authors are invited to contribute original basic research, prospective studies, and systematic reviews in the field of pharmacological approaches to cardiac and vascular diseases by outlining the most recent advances in therapies and treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)